Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21991

Shown on this page

Current sort

Live official records

Open in full search

Conditions: PreDiabetes
Interventions: CGM-DPP, Control; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Interventions: ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator; Device · Procedure
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Atrial Fibrillation
Interventions: VARIPULSE Catheter, FARAWAVE Catheter; Device
Lead sponsor: Biosense Webster, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Fountain Valley, California • Ventura, California + 16 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Interventions: Pirtobrutinib, Venetoclax, Obinutuzumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Fludeoxyglucose F-18, Biospecimen Collection; Drug · Other · Radiation + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 125
States / cities: Jonesboro, Arkansas • Los Angeles, California • Parker, Colorado + 95 more

Conditions: Post Traumatic Stress Disorder
Interventions: TSND-201, Placebo; Drug
Lead sponsor: Transcend Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Denver, Colorado • Bradenton, Florida • Orlando, Florida + 5 more

Conditions: Psychiatric Problem
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 15 Years to 23 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: B Cell Lymphoma
Interventions: Glofitamab, Obinutuzumab, Axi-cel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atherosclerosis
Interventions: Selnoflast, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more

Conditions: Gastrointestinal Diseases, Chest Pain
Interventions: Virtual Reality; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Interventions: Guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 6
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Cincinnati, Ohio + 2 more

Conditions: KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer), NSCLC, NSCLC (Non-small-cell Lung Cancer), NSCLC Non-small Cell Lung Cancer, Lung Cancer (Non-Small Cell), KRAS G12-mutant NSCLC
Interventions: KQB365, Cetuximab, KQB198; Drug
Lead sponsor: Kumquat Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more

Recruiting clinical trials

Filter and sort this status page

Live official records

CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

Environmental Mixtures, Cognitive Control and Reward Processes, and Risk for Psychiatric Problems in Adolescence

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

Virtual Reality for Non-cardiac Chest Pain

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies